Next Article in Journal
Recent Progress in Discovering the Role of Carotenoids and Metabolites in Prostatic Physiology and Pathology—A Review—Part II: Carotenoids in the Human Studies
Next Article in Special Issue
13R,20-Dihydroxydocosahexaenoic Acid, a Novel Dihydroxy- DHA Derivative, Inhibits Breast Cancer Stemness through Regulation of the Stat3/IL-6 Signaling Pathway by Inducing ROS Production
Previous Article in Journal
Health Potential of Aloe vera against Oxidative Stress Induced Corneal Damage: An “In Vitro” Study
Previous Article in Special Issue
Antioxidants for the Treatment of Breast Cancer: Are We There Yet?
Article

xCT-Driven Expression of GPX4 Determines Sensitivity of Breast Cancer Cells to Ferroptosis Inducers

1
Cell and Cancer Biology, Department of Molecular, University of Massachusetts Medical School, Worcester, MA 01604, USA
2
Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01604, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Sergio Granados-Principal
Antioxidants 2021, 10(2), 317; https://doi.org/10.3390/antiox10020317
Received: 20 January 2021 / Revised: 14 February 2021 / Accepted: 17 February 2021 / Published: 20 February 2021
(This article belongs to the Special Issue Antioxidants for Breast Cancer)
Inducers of ferroptosis such as the glutathione depleting agent Erastin and the GPX4 inhibitor Rsl-3 are being actively explored as potential therapeutics in various cancers, but the factors that determine their sensitivity are poorly understood. Here, we show that expression levels of both subunits of the cystine/glutamate antiporter xCT determine the expression of GPX4 in breast cancer, and that upregulation of the xCT/selenocysteine biosynthesis/GPX4 production axis paradoxically renders the cancer cells more sensitive to certain types of ferroptotic stimuli. We find that GPX4 is strongly upregulated in a subset of breast cancer tissues compared to matched normal samples, and that this is tightly correlated with the increased expression of the xCT subunits SLC7A11 and SLC3A2. Erastin depletes levels of the antioxidant selenoproteins GPX4 and GPX1 in breast cancer cells by inhibiting xCT-dependent extracellular reduction which is required for selenium uptake and selenocysteine biosynthesis. Unexpectedly, while breast cancer cells are resistant compared to nontransformed cells against oxidative stress inducing drugs, at the same time they are hypersensitive to lipid peroxidation and ferroptosis induced by Erastin or Rsl-3, indicating that they are ‘addicted’ to the xCT/GPX4 axis. Our findings provide a strategic basis for targeting the anti-ferroptotic machinery of breast cancer cells depending on their xCT status, which can be further explored. View Full-Text
Keywords: ferroptosis; GPX4; Erastin; Rsl-3; breast cancer; selenium; lipid peroxidation ferroptosis; GPX4; Erastin; Rsl-3; breast cancer; selenium; lipid peroxidation
Show Figures

Figure 1

MDPI and ACS Style

Lee, N.; Carlisle, A.E.; Peppers, A.; Park, S.J.; Doshi, M.B.; Spears, M.E.; Kim, D. xCT-Driven Expression of GPX4 Determines Sensitivity of Breast Cancer Cells to Ferroptosis Inducers. Antioxidants 2021, 10, 317. https://doi.org/10.3390/antiox10020317

AMA Style

Lee N, Carlisle AE, Peppers A, Park SJ, Doshi MB, Spears ME, Kim D. xCT-Driven Expression of GPX4 Determines Sensitivity of Breast Cancer Cells to Ferroptosis Inducers. Antioxidants. 2021; 10(2):317. https://doi.org/10.3390/antiox10020317

Chicago/Turabian Style

Lee, Namgyu, Anne E. Carlisle, Austin Peppers, Sung J. Park, Mihir B. Doshi, Meghan E. Spears, and Dohoon Kim. 2021. "xCT-Driven Expression of GPX4 Determines Sensitivity of Breast Cancer Cells to Ferroptosis Inducers" Antioxidants 10, no. 2: 317. https://doi.org/10.3390/antiox10020317

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop